NCT03043872 2026-04-22
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
132 trialsNCT04988295 2026-04-22
MARIPOSA-2
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05687266 2026-04-22
AVANZAR
AstraZeneca
Phase 3 Active not recruiting
NCT06225596 2026-04-22
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2/3 Active not recruiting
NCT06607185 2026-04-22
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04765059 2026-04-21
COMPEL
AstraZeneca
Phase 3 Active not recruiting
NCT05771480 2026-04-21
TOURMALINE
AstraZeneca
Phase 3 Active not recruiting
NCT02516241 2026-04-20
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT03485209 2026-04-20
innovaTV 207
Seagen Inc.
Phase 2 Active not recruiting
NCT05911295 2026-04-20
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
NCT03967977 2026-04-17
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
BeOne Medicines
Phase 3 Active not recruiting
NCT06382116 2026-04-17
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06449209 2026-04-17
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
NCT05635708 2026-04-15
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Active not recruiting
NCT06151574 2026-04-15
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Phase 3 Active not recruiting
NCT06077500 2026-04-14
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT02609776 2026-04-13
CHRYSALIS
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03393884 2026-04-13
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT04077463 2026-04-13
Chrysalis-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04538664 2026-04-13
PAPILLON
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05595460 2026-04-13
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
RayzeBio, Inc.
Phase 1 Active not recruiting
NCT04083599 2026-04-08
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-04-08
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT05083481 2026-04-08
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT06057038 2026-04-08
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting
NCT06624059 2026-04-08
HORIZON 2
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04612751 2026-04-06
TROPION-Lung04
AstraZeneca
Phase 1 Active not recruiting
NCT04938583 2026-04-06
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Active not recruiting
NCT05181462 2026-04-06
TRIFOUR
Cantargia AB
Phase 1/2 Active not recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT05382299 2026-04-06
ASCENT-03
Gilead Sciences
Phase 3 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT05048797 2026-04-03
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
AstraZeneca
Phase 3 Active not recruiting
NCT06112379 2026-04-02
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT04498117 2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT05605535 2026-04-01
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
CanariaBio Inc.
Phase 2 Active not recruiting
NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT03473743 2026-03-30
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT04129502 2026-03-30
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
Takeda
Phase 3 Active not recruiting
NCT04736173 2026-03-30
ARC-10
Arcus Biosciences, Inc.
Phase 2 Active not recruiting
NCT05815160 2026-03-30
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Debiopharm International SA
Phase 1 Active not recruiting
NCT06008093 2026-03-30
TRITON
AstraZeneca
Phase 2 Active not recruiting
NCT05017012 2026-03-27
MK-3475A-C18
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT05555732 2026-03-25
TROPION-Lung07
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06396065 2026-03-24
Phase III Study of AK112 for NSCLC Patients
Summit Therapeutics
Phase 3 Active not recruiting
NCT04379635 2026-03-18
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
BeOne Medicines
Phase 3 Active not recruiting
NCT06726265 2026-03-18
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Immutep S.A.S.
Phase 3 Active not recruiting
NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
NCT05984277 2026-03-17
eVOLVE-Lung02
AstraZeneca
Phase 3 Active not recruiting
NCT03164616 2026-03-13
POSEIDON
AstraZeneca
Phase 3 Active not recruiting